More Topics:
NeuroMetrix Is Better Positioned After Share Raise
Posted February 9, 2012
We Recommend...
Shai N. Gozani
By Paul Nouri
Yesterday morning, NeuroMetrix (NURO) announced that the company was able to raise more than $10,000,000 by offering 10,500,000 shares at $1 per share, plus warrants. While this was more than 10% lower than the prior day's closing price, it should comfort long term investors that the company now has what should be enough money to manage through 2-3 years of losses until the company's primary product, NC-Stat DPN Check, can reach a critical mass in sales. Additionally, the fact that management was able to convince a new round of investors that their product can be successful in the market place bodes well for the company.
The potential for a dilutive capital raise has been one major hurdle for investors looking at the company prior to today's announcement. However, I think that the primary focal point for all investors is the chance of success of the company's primary product, NC-Stat DPNCheck. It is the first product of its type that can accurately evaluate diabetic peripheral neuropathy in the doctor's office. READ FULL ARTICLE HERE
blog comments powered by